Techbio company Genomics has partnered with biotech company Greywolf Therapeutics to advance novel antigen modulation treatments to treat autoimmune diseases. Under the agreement, Genomics is set to curate and analyse large-scale genetic datasets to assess how variants of the ERAP (Endoplasmic Reticulum Aminopeptidases) enzymes influence disease risk across multiple autoimmune conditions. ERAP1 and ERAP2 are key […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!